¡ú@Hiroshi_Tsuji¡ÊºÆ´¶À÷¥¨¥Ó¥Ç¥ó¥¹¡Ë ¥¤¥ó¥É¤«¤é¤â¿··¿¥³¥í¥ÊºÆ´¶À÷»öÎã¤ÎÊó¹ð½Ð¤Þ¤·¤¿¡£°åÎŽ¾»ö¼Ô2¿Í¡¢1ÅÙÌÜ2ÅÙÌܤδ¶À÷¶¦¤Ë̵¾É¾õ¤À¤¬¡¢PCR¸¡ºº»þ¤ÎCtÃͤ«¤é¤Ç¤¹¤¬2²óÌܤδ¶À÷»þ¤Î¥¦¥¤¥ë¥¹Î̤¬2¿Í¤È¤â1ÅÙÌܤè¤ê¿¤«¤Ã¤¿»ö¤¬ÃíÌܤµ¤ì¤Æ¤Þ¤¹¡£¤³¤Á¤é¤ÎÊó¹ð¤â¥²¥Î¥à²òÀϤˤưۤʤ륦¥¤¥ë¥¹¤È¡£ @VirusesImmunity Report by @vinodscaria shows 2 cases of #reinfection by #SARS_CoV_2. Both were asymptomatic after first and second infection. Curiously the reinfection in both cases led to much higher viral load than the first infection. These results emphasize the need for more surveillance.
¡ú@hrkz1985¡Ê¥¢¥Ó¥¬¥ó¡Ë ·Ú¾ÉCOVID-19¤ËÂФ¹¤ë¥¢¥Ó¥¬¥ó¤Î¸ú²Ì¤ò¸¡Æ¤¤·¤¿RCT¡£È¯¾É¤«¤é̵ºî°Ù²½¤Þ¤Ç¤ÎÃæ±ûÃͤÏ7Æü´Ö¡£¼£Îų«»Ï¤«¤é6Æü»þÅÀ¤Ç¤ÎPCR±¢À²½¤Ï¡¢¸å´ü¼£Îų«»Ï·²¡Ê̵ºî°Ù²½¤«¤é6ÆüÌܤÇÅêÍ¿³«»Ï¡Ë¤ÈƱÅù¡¢²òÇ®¤Ï1ÆüÁá¤Þ¤Ã¤¿¡£·Ú¾ÉÎã¤ËÂФ¹¤ëÎ×¾²Åª¤ËÍÍÑÀ¤Ï¤Û¤Ü¤Ê¤¤¡£»ÄÇ°¡£ A prospective, randomized, open-label trial of early versus late... https://aac.asm.org/content/early/2020/09/16/AAC.01897-20 ¢¬ ¡ú@hichachu ËÜʸ¤Î¹Í»¡¤òÆɤà¤È¡¢¤½¤ìÄø¤ÎÈá´ÑŪ¤Ê¥Ë¥å¥¢¥ó¥¹¤Ë¤Ï½ñ¤«¤ì¤Æ¤¤¤Þ¤»¤ó¡¢ #¥¢¥Ó¥¬¥ó
¡ú@ygjumi #COVID19 ºÆ´¶À÷¤ÎµÏ¿ ¸½ºß¡¢³Îǧ¤µ¤ì¤¿ºÆ´¶À÷¾ÉÎã¤Ï11 ¤¦¤Á¡¢4¾ÉÎ㤬¡¢ºÆ´¶À÷»þ¤Ë°²½ @DrEricDing RE-INFECTION TRACKER—now 11: There has now been 11 documented cases of #SARSCoV2 infection. @BNONews has been tracking such clinical reinfections of #COVID19. By BNO unofficial tabulation, there are now 11, 4 of which suffered more severe 2nd infection. https://bnonews.com/index.php/2020/08/covid-19-reinfection-tracker/